Media Center, NovaMedica

Top news

NovaMedica to localize in Russia one of the most popular anti-migraine drugs in the world

21-March-2023

March 21, 2023, Moscow – Russian pharmaceutical company NovaMedica (investment project of RUSNANO) registered its own-development product Relonova (INN Rizatriptan) for migraine-related headache relief. This is the first Rizatriptan-based drug in Russia that is fully localized in the country, from development to manufacturing and introduction in prescription practice. Relonova will be manufactured in Moscow at the Technological Center NovaMedica Innotech (100% subsidiary of NovaMedica), which will enable uninterrupted supplies of the drug and its availability for Russian patients.
NovaMedica registers two own-development CNS products, one without equivalents in Russia and the other – in the world

15-December-2022

Russian pharmaceutical company NovaMedica (RUSNANO portfolio company) has developed and registered two innovative drugs to combat disorders of the central nervous system (CNS): Difendum® for pain relief and Levroso® Long for insomnia therapy. The products will be manufactured in Russia by the Technology Center NovaMedica Innotech (100% subsidiary of NovaMedica).